Susanna Ulahannan, MD
Hematology & Oncology · Ponca City, OKNPI 1033369988
Payments from drug & device makers
Across 2,078 payments — averaging $3999.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$2.7M
- Exelixis Inc.$1.1M
- Merck$900K
- Bristol Myers Squibb$833K
- Regeneron$568K
- Takeda Pharmaceuticals U.S.A., Inc.$533K
- plus $1.7M from 27 others
Across 4 payments — averaging $1395.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$5K
- Regeneron$675
- Eli Lilly$402
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 738 | $2,673,440 |
| Exelixis Inc. | 499 | $1,098,380 |
| Merck | 103 | $899,640 |
| Bristol Myers Squibb | 11 | $833,031 |
| Regeneron | 144 | $567,843 |
| Takeda Pharmaceuticals U.S.A., Inc. | 124 | $533,003 |
| E.r. Squibb & Sons, L.L.C. | 9 | $395,985 |
| Macrogenics, Inc. | 123 | $331,600 |
| Janssen Research & Development, LLC | 57 | $198,715 |
| AstraZeneca | 12 | $179,815 |
| Incyte Corporation | 123 | $151,092 |
| AbbVie | 8 | $110,474 |
| Pfizer | 27 | $85,197 |
| Roche Products Limited | 26 | $79,813 |
| Otsuka Pharmaceutical Co., Ltd. | 15 | $59,738 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 7 | $40,690 |
| Exthera Medical Corporation | 1 | $23,000 |
| G1 Therapeutics, Inc. | 24 | $18,611 |
| Eli Lilly | 4 | $10,083 |
| Genentech, Inc. | 4 | $6,515 |
| Eisai Inc. | 4 | $5,095 |
| Boehringer Ingelheim | 2 | $3,595 |
| Vividion Therapeutics Inc. | 1 | $2,000 |
| Bayer | 2 | $1,616 |
| Jazz Pharmaceuticals Inc. | 1 | $1,080 |
| Array Biopharma Inc | 2 | $155 |
| Histosonics, Inc. | 1 | $135 |
| Caris MPI, Inc. | 1 | $133 |
| Gilead | 1 | $100 |
| Genentech USA, Inc. | 1 | $25 |
| Alcresta Therapeutics, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
How this compares
$8,310,664 in reported general payments places this provider in the 95th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Ponca City
- Akinola OgundipePonca City$10K
- Adam AschOklahoma City$2M
- Adanma Anji Ayanambakkam AttanathiOklahoma City$1.9M
- Kevin WeibelTulsa$1.7M
- Hassan HatoumOklahoma City$1.4M
- Abdul Rafeh NaqashOklahoma City$1.1M
- Sami IbrahimiOklahoma City$1M
- Scott ColeTulsa$644K
- Carrie YuenOklahoma City$564K
- Than AyeLawton$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.